Výsledky vyhledávání - "Ashok K. Vaid"

Akademický článek

Indian Expert Opinion on Cancer Care during COVID-19 Pandemic

Autor: Ashok K. Vaid, Hemant Malhotra, Raja Thirumalairaj, Reena Nair, Ajay Bapna, Senthil J. Rajappa, S. P. Somashekhar, Chanchal Goswami, Jyoti Bajpai

Publikováno v: South Asian Journal of Cancer, Vol 10, Iss 01, Pp 09-18 (2021)

Coronavirus pandemic has increased human disease burden, as well as economic distress globally. Being in an immunocompromised state, patients with cancer comprise an important at-risk population for novel coronavirus disease 2019 (COVID-19) infection

Externí odkaz: https://doaj.org/article/7bd2e868318c40c6869f000c4a0eee14

Zobrazit plný text záznamu

Akademický článek

Expert Consensus on Effective Management of Chemotherapy-Induced Nausea and Vomiting: An Indian Perspective

Autor: Ashok K. Vaid, Sudeep Gupta, Dinesh C. Doval, Shyam Agarwal, Shona Nag, Poonam Patil, Chanchal Goswami, Vikas Ostwal, Sagar Bhagat, Saiprasad Patil, Hanmant Barkate

Publikováno v: Frontiers in Oncology, Vol 10 (2020)

Chemotherapy-induced nausea and vomiting (CINV) is one of the most common and feared side effects in cancer patients undergoing chemotherapy. Scientific evidence proves its detrimental impact on a patient's quality of life (QoL), treatment compliance

Externí odkaz: https://doaj.org/article/c01e4fab1a6f412cb607a173ecb8b6f4

Zobrazit plný text záznamu

Abstract P4-07-62: Real-World, Single-Center Experience on the Outcomes of Neoadjuvant Chemotherapy and Trastuzumab alone or in Combination with Pertuzumab in Human Epidermal Growth Factor Receptor 2 Breast Cancer Patients

Autor: Ashok K. Vaid, Devender Sharma, Jyoti Wadhwa, Rajeev Agarwal, Kanchan Kaur, Shina Goyal, Dheeraj Gautam, Jyoti Arora, Sabhyata Gupta, Ashok Sen, Ruchika K. Goel, Shagun Mahajan

Publikováno v: Cancer Research. 83:P4-07

Background: Neoadjuvant chemotherapy is the standard of care for early stage breast cancer. Human epidermal growth factor receptor 2 (HER2) positive disease constitutes a large proportion of breast cancer patients, and HER2 overexpression is associat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::560aac71e28aca8ab78db3456ececa7c
https://doi.org/10.1158/1538-7445.sabcs22-p4-07-62

Zobrazit plný text záznamu

XAI-MethylMarker: Explainable AI approach for biomarker discovery for breast cancer subtype classification using methylation data

Autor: Sheetal Rajpal, Ankit Rajpal, Arpita Saggar, Ashok K. Vaid, Virendra Kumar, Manoj Agarwal, Naveen Kumar

Publikováno v: Expert Systems with Applications. 225:120130

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::37eba03e0823050516c937546fe911e9
https://doi.org/10.1016/j.eswa.2023.120130

Zobrazit plný text záznamu

Sensitivity to differential NRF1 gene signatures contributes to breast cancer disparities

Autor: Robert J. Poppiti, Deodutta Roy, Indu Shekhar Thakur, Changwon Yoo, Ashok K. Vaid, Ricardo J. Komotar, Zhenghua Gong, Quentin Felty, Juan P. Liuzzi, Ruchika Goel, Nasreen Z. Ehtesham, Jairo Ramos, Seyed Ehtesham Hasnain

Publikováno v: Journal of Cancer Research and Clinical Oncology. 146:2777-2815

Nuclear respiratory factor 1 (NRF1) drives estrogen-dependent breast tumorigenesis. Herein we examined the impact of NRF1 activity on the aggressiveness and disparate molecular signature of breast cancer in Black, White, Asian, and Hispanic women. NR

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3d036a51b39183919002358b976f9220
https://doi.org/10.1007/s00432-020-03320-9

Zobrazit plný text záznamu

Biomarkers in Non-Small Cell Lung Cancers: Indian Consensus Guidelines for Molecular Testing

Autor: Vamshi Muddu, T. P. Sahoo, Bivas Biswas, Mithua Ghosh, Ashok K. Vaid, Suresh H. Advani, Ullas Batra, Anuradha Chougule, Kumar Prabhash

Publikováno v: Advances in Therapy. 36:766-785

Novel molecular targets and promising targeted therapies have reshaped diagnostics in patients with advanced non-small cell lung cancer (NSCLC). Despite this progress, the implementation of molecular screening to identify predictive biomarkers in Ind

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b48d223ec909cc764406da29d87edd65
https://doi.org/10.1007/s12325-019-00903-y

Zobrazit plný text záznamu

Efficacy and safety of palbociclib in treatment of HR-positive advanced breast cancer patients: A single center real-world experience

Autor: Ashok K. Vaid, Devender Sharma, Jyoti Wadhwa, Nagender Sharma, Saurabh Mishra, Dheeraj Gautam, Ashok Sen, Anisha Raju, Lavina Yadav, Girdhar Verma

Publikováno v: Journal of Clinical Oncology. 40:e13035-e13035

e13035 Background: With an estimated 2.3 million new cases (11.7% of all cases), female breast cancer is the leading cause of cancer globally as of 2020. Metastatic or advanced breast cancer is an incurable disease with a 5-year overall survival rate

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::81de6fbc15c86ff3377e64698df52477
https://doi.org/10.1200/jco.2022.40.16_suppl.e13035

Zobrazit plný text záznamu

Overall survival in stage IV EGFR mutation‑positive NSCLC: Comparing first‑, second‑ and third‑generation EGFR‑TKIs (Review)

Autor: Ashok K. Vaid, Gagandeep Momi, Alok Gupta

Publikováno v: International journal of oncology. 58(2)

A substantial (40‑60%) proportion of patients with non‑small cell lung carcinoma (NSCLC) have epidermal growth factor receptor (EGFR) mutations, a crucial therapeutic target in NSCLC. Treatment strategies for patients with advanced‑stage NSCLC

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::839a8381477831f9904de0d8518c76db
https://pubmed.ncbi.nlm.nih.gov/33491758

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání